UrologiePub Date : 2024-11-01DOI: 10.1007/s00120-024-02468-3
{"title":"BvDU Kurz notiert.","authors":"","doi":"10.1007/s00120-024-02468-3","DOIUrl":"10.1007/s00120-024-02468-3","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 11","pages":"1191-1192"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-11-01DOI: 10.1007/s00120-024-02466-5
{"title":"Mitteilungen der DGU.","authors":"","doi":"10.1007/s00120-024-02466-5","DOIUrl":"10.1007/s00120-024-02466-5","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 11","pages":"1175-1190"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-11-01Epub Date: 2024-10-10DOI: 10.1007/s00120-024-02455-8
Michael Zitzmann, Martin C Michel, Herbert Sperling
{"title":"[Testosterone replacement therapy and possible side effects].","authors":"Michael Zitzmann, Martin C Michel, Herbert Sperling","doi":"10.1007/s00120-024-02455-8","DOIUrl":"10.1007/s00120-024-02455-8","url":null,"abstract":"<p><p>The substitution of testosterone is basic andrological treatment. Beside the \"when and how,\" knowledge of possible side effects is mandatory. Therefore, we highlight the effects of testosterone replacement therapy on bones, cardiac function, sexuality, gynacomatia, fertility, and contraception, but also areas of concern regarding prostate carcinoma and testosterone replacement therapy.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1103-1110"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-10-10DOI: 10.1007/s00120-024-02462-9
Paulo Leonardo Pfitzinger, Darjusch Andreas Askari, Troya Ivanova, Marina Hoffmann, Iulia Blajan, Michael Atzler, Leo Federico Stadelmeier, Maria Apfelbeck, Michael Chaloupka, Philipp Kazmierczak, Christian Stief, Benazir Enzinger
{"title":"Erratum zu: Perineale Prostatabiopsie.","authors":"Paulo Leonardo Pfitzinger, Darjusch Andreas Askari, Troya Ivanova, Marina Hoffmann, Iulia Blajan, Michael Atzler, Leo Federico Stadelmeier, Maria Apfelbeck, Michael Chaloupka, Philipp Kazmierczak, Christian Stief, Benazir Enzinger","doi":"10.1007/s00120-024-02462-9","DOIUrl":"https://doi.org/10.1007/s00120-024-02462-9","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-10-01Epub Date: 2024-10-07DOI: 10.1007/s00120-024-02442-z
Günter Niegisch, Mario Kramer
{"title":"[Current developments in urothelial carcinoma].","authors":"Günter Niegisch, Mario Kramer","doi":"10.1007/s00120-024-02442-z","DOIUrl":"https://doi.org/10.1007/s00120-024-02442-z","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 10","pages":"975-976"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-10-01Epub Date: 2024-08-26DOI: 10.1007/s00120-024-02416-1
G Niegisch, C Bolenz, C Doehn, G Gakis, A Hartmann, H Müller-Huesmann, H Reis, F Roghmann, K Schwamborn, K Tiemann, M Retz
{"title":"[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].","authors":"G Niegisch, C Bolenz, C Doehn, G Gakis, A Hartmann, H Müller-Huesmann, H Reis, F Roghmann, K Schwamborn, K Tiemann, M Retz","doi":"10.1007/s00120-024-02416-1","DOIUrl":"10.1007/s00120-024-02416-1","url":null,"abstract":"<p><p>The risk of recurrence in patients with muscle invasive bladder cancer (MIBC) after radical cystectomy depends on the pathological tumor stage. In particular, patients with lymph node metastasis (pN+), locally advanced (≥pT3), or residual muscle invasive tumor despite neoadjuvant chemotherapy are at high risk. Currently, the importance of adjuvant therapy with immune checkpoint inhibitors is increasing in the context of perioperative systemic therapeutic concepts. The indication for the PD‑1 inhibitor nivolumab currently approved in the European Union requires testing of PD-L1 (programmed cell death ligand 1) protein expression by immunochemistry in tumor tissue. Focusing on MIBC patients at high risk of recurrence, new questions arise regarding the implementation and interpretation of PD-L1 testing. An interdisciplinary group of experts from Germany has discussed relevant issues from a clinicopathological point of view and developed practical recommendations to facilitate the implementation of validated and quality-assured PD-L1 testing for the approved indications in daily clinical practice.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1019-1027"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：